<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02303002</url>
  </required_header>
  <id_info>
    <org_study_id>RT002-CL002</org_study_id>
    <secondary_id>CTA Control No. 179120</secondary_id>
    <secondary_id>File No. 9427-R1312\1-22C</secondary_id>
    <nct_id>NCT02303002</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revance Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Revance Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a safety and efficacy study of botulinum toxin type A in subjects with glabellar
      frown lines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects assessed as responders by investigator assessment of severity of glabellar lines at maximum frown</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response assessed by investigator assessment of severity of glabellar lines at maximum frown from the date of injection to when subject reverts to baseline severity</measure>
    <time_frame>Up to Week 36</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">268</enrollment>
  <condition>Glabellar Frown Lines</condition>
  <arm_group>
    <arm_group_label>Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose A: Botulinum Toxin Type A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose B: Botulinum Toxin Type A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose C: Botulinum Toxin Type A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose D: Botulinum Toxin Type A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose E: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <description>Intramuscular injection (IM)</description>
    <arm_group_label>Dose A</arm_group_label>
    <arm_group_label>Dose B</arm_group_label>
    <arm_group_label>Dose C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Active Comparator botulinum toxin</intervention_name>
    <description>IM injection</description>
    <arm_group_label>Dose D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>IM injection</description>
    <arm_group_label>Dose E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate or severe glabellar frown lines

          -  Female or male, 30 to 65 years of age in good general health

          -  Women of childbearing potential must agree to use an effective method of birth control
             during the course of the study

          -  Willing to refrain from receipt of facial fillers, laser treatments or use of products
             that affect skin remodeling and causes an active dermal response

        Exclusion Criteria:

          -  Any neurological condition that may place the subject at increased risk with exposure
             to Botulinum Toxin Type A such as amyotrophic lateral sclerosis and motor neuropathy,
             Lambert-Eaton syndrome, and myasthenia gravis

          -  Muscle weakness or paralysis, particularly in the treatment area

          -  Active skin disease or infections or irritation at the treatment area

          -  Facial asymmetry, deep dermal scarring, or inability to substantially lessen the
             glabellar frown lines by manually spreading them apart

          -  Treatment with Botulinum Toxin Type A in the face in the last 6 months or in the last
             3 months anywhere in the body
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2014</study_first_submitted>
  <study_first_submitted_qc>November 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2014</study_first_posted>
  <last_update_submitted>March 8, 2016</last_update_submitted>
  <last_update_submitted_qc>March 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

